Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cardiology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis

Abstract

Introduction

Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as PubMed and the Cochrane Library, were used to conduct a thorough search.

Method

This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.

Results

Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.

Conclusion

In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X345749250122092324
2025-02-11
2025-04-22

  • From This Site

    /content/journals/ccr/10.2174/011573403X345749250122092324
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Borén J. Chapman M.J. Krauss R.M. Packard C.J. Bentzon J.F. Binder C.J. Daemen M.J. Demer L.L. Hegele R.A. Nicholls S.J. Nordestgaard B.G. Watts G.F. Bruckert E. Fazio S. Ference B.A. Graham I. Horton J.D. Landmesser U. Laufs U. Masana L. Pasterkamp G. Raal F.J. Ray K.K. Schunkert H. Taskinen M.R. van de Sluis B. Wiklund O. Tokgozoglu L. Catapano A.L. Ginsberg H.N. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2020 41 24 2313 2330 10.1093/eurheartj/ehz962 32052833
    [Google Scholar]
  2. Khan S.U. Yedlapati S.H. Lone A.N. Hao Q. Guyatt G. Delvaux N. Bekkering G.E.T. Vandvik P.O. Riaz I.B. Li S. Aertgeerts B. Rodondi N. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis. BMJ 2022 377 e069116 10.1136/bmj‑2021‑069116 35508321
    [Google Scholar]
  3. Hameed I. Shah S.A. Aijaz A. Mushahid H. Farhan S.H. Dada M. Khan A.B. Amjad R. Alvi F. Murtaza M. Zuberi Z. Hamza M. Comparative safety and efficacy of low/moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: An updated meta-analysis. Am. J. Cardiovasc. Drugs 2024 24 3 419 431 10.1007/s40256‑024‑00642‑8 38578578
    [Google Scholar]
  4. Roh E. Ko S.H. Kwon H.S. Kim N.H. Kim J.H. Kim C.S. Song K.H. Won J.C. Kim D.J. Choi S.H. Lim S. Cha B.Y. Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. Diabetes Metab. J. 2013 37 6 433 449 10.4093/dmj.2013.37.6.433 24404515
    [Google Scholar]
  5. Ah Y.M. Jeong M. Choi H.D. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies. PLoS One 2022 17 3 e0264437 10.1371/journal.pone.0264437 35245303
    [Google Scholar]
  6. Baigent C. Blackwell L. Emberson J. Holland L.E. Reith C. Bhala N. Peto R. Barnes E.H. Keech A. Simes J. Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010 376 9753 1670 1681 10.1016/S0140‑6736(10)61350‑5 21067804
    [Google Scholar]
  7. Grundy S.M. Stone N.J. Bailey A.L. Beam C. Birtcher K.K. Blumenthal R.S. Braun L.T. de Ferranti S. Faiella-Tommasino J. Forman D.E. Goldberg R. Heidenreich P.A. Hlatky M.A. Jones D.W. Lloyd-Jones D. Lopez-Pajares N. Ndumele C.E. Orringer C.E. Peralta C.A. Saseen J.J. Smith S.C. Jr Sperling L. Virani S.S. Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive summary. J. Am. Coll. Cardiol. 2019 73 24 3168 3209 10.1016/j.jacc.2018.11.002 30423391
    [Google Scholar]
  8. Hur K.Y. Moon M.K. Park J.S. Kim S.K. Lee S.H. Yun J.S. Baek J.H. Noh J. Lee B.W. Oh T.J. Chon S. Yang Y.S. Son J.W. Choi J.H. Song K.H. Kim N.H. Kim S.Y. Kim J.W. Rhee S.Y. Lee Y.B. Jin S.M. Kim J.H. Kim C.H. Kim D.J. Chun S. Rhee E.J. Kim H.M. Kim H.J. Jee D. Kim J.H. Choi W.S. Lee E.Y. Yoon K.H. Ko S.H. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes Metab. J. 2021 45 4 461 481 10.4093/dmj.2021.0156 34352984
    [Google Scholar]
  9. Sampson U.K. Fazio S. Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep. 2012 14 1 1 10 10.1007/s11883‑011‑0219‑7 22102062
    [Google Scholar]
  10. Anderson T.J. Grégoire J. Pearson G.J. Barry A.R. Couture P. Dawes M. Francis G.A. Genest J. Jr Grover S. Gupta M. Hegele R.A. Lau D.C. Leiter L.A. Lonn E. Mancini G.B.J. McPherson R. Ngui D. Poirier P. Sievenpiper J.L. Stone J.A. Thanassoulis G. Ward R. 2016 Canadian Cardiovascular Society guidelines for managing dyslipidemia to prevent cardiovascular disease in the adult. Can. J. Cardiol. 2016 32 11 1263 1282 10.1016/j.cjca.2016.07.510 27712954
    [Google Scholar]
  11. Wong N.D. Zhao Y. Quek R.G.W. Blumenthal R.S. Budoff M.J. Cushman M. Garg P. Sandfort V. Tsai M. Lopez J.A.G. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. J. Clin. Lipidol. 2017 11 5 1223 1233 10.1016/j.jacl.2017.06.015 28754224
    [Google Scholar]
  12. Mach F. Baigent C. Catapano A.L. Koskinas K.C. Casula M. Badimon L. Chapman M.J. De Backer G.G. Delgado V. Ference B.A. Graham I.M. Halliday A. Landmesser U. Mihaylova B. Pedersen T.R. Riccardi G. Richter D.J. Sabatine M.S. Taskinen M.R. Tokgozoglu L. Wiklund O. Mueller C. Drexel H. Aboyans V. Corsini A. Doehner W. Farnier M. Gigante B. Kayikcioglu M. Krstacic G. Lambrinou E. Lewis B.S. Masip J. Moulin P. Petersen S. Petronio A.S. Piepoli M.F. Pintó X. Räber L. Ray K.K. Reiner Ž. Riesen W.F. Roffi M. Schmid J-P. Shlyakhto E. Simpson I.A. Stroes E. Sudano I. Tselepis A.D. Viigimaa M. Vindis C. Vonbank A. Vrablik M. Vrsalovic M. Zamorano J.L. Collet J-P. Koskinas K.C. Casula M. Badimon L. John Chapman M. De Backer G.G. Delgado V. Ference B.A. Graham I.M. Halliday A. Landmesser U. Mihaylova B. Pedersen T.R. Riccardi G. Richter D.J. Sabatine M.S. Taskinen M-R. Tokgozoglu L. Wiklund O. Windecker S. Aboyans V. Baigent C. Collet J-P. Dean V. Delgado V. Fitzsimons D. Gale C.P. Grobbee D. Halvorsen S. Hindricks G. Iung B. Jüni P. Katus H.A. Landmesser U. Leclercq C. Lettino M. Lewis B.S. Merkely B. Mueller C. Petersen S. Petronio A.S. Richter D.J. Roffi M. Shlyakhto E. Simpson I.A. Sousa-Uva M. Touyz R.M. Nibouche D. Zelveian P.H. Siostrzonek P. Najafov R. van de Borne P. Pojskic B. Postadzhiyan A. Kypris L. Špinar J. Larsen M.L. Eldin H.S. Viigimaa M. Strandberg T.E. Ferrières J. Agladze R. Laufs U. Rallidis L. Bajnok L. Gudjónsson T. Maher V. Henkin Y. Gulizia M.M. Mussagaliyeva A. Bajraktari G. Kerimkulova A. Latkovskis G. Hamoui O. Slapikas R. Visser L. Dingli P. Ivanov V. Boskovic A. Nazzi M. Visseren F. Mitevska I. Retterstøl K. Jankowski P. Fontes-Carvalho R. Gaita D. Ezhov M. Foscoli M. Giga V. Pella D. Fras Z. de Isla L.P. Hagström E. Lehmann R. Abid L. Ozdogan O. Mitchenko O. Patel R.S. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020 41 1 111 188 10.1093/eurheartj/ehz455 31504418
    [Google Scholar]
  13. Giugliano R.P. Pedersen T.R. Park J.G. De Ferrari G.M. Gaciong Z.A. Ceska R. Toth K. Gouni-Berthold I. Lopez-Miranda J. Schiele F. Mach F. Ott B.R. Kanevsky E. Pineda A.L. Somaratne R. Wasserman S.M. Keech A.C. Sever P.S. Sabatine M.S. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet 2017 390 10106 1962 1971 10.1016/S0140‑6736(17)32290‑0 28859947
    [Google Scholar]
  14. Rosenson R.S. Hegele R.A. Fazio S. Cannon C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol. 2018 72 3 314 329 10.1016/j.jacc.2018.04.054 30012326
    [Google Scholar]
  15. Stroes E.S. Thompson P.D. Corsini A. Vladutiu G.D. Raal F.J. Ray K.K. Roden M. Stein E. Tokgözoğlu L. Nordestgaard B.G. Bruckert E. De Backer G. Krauss R.M. Laufs U. Santos R.D. Hegele R.A. Hovingh G.K. Leiter L.A. Mach F. März W. Newman C.B. Wiklund O. Jacobson T.A. Catapano A.L. Chapman M.J. Ginsberg H.N. Stroes E. Thompson P.D. Corsini A. Vladutiu G.D. Raal F.J. Ray K.K. Roden M. Stein E. Tokgözoğlu L. Nordestgaard B.G. Bruckert E. Krauss R.M. Laufs U. Santos R.D. März W. Newman C.B. John Chapman M. Ginsberg H.N. John Chapman M. Ginsberg H.N. de Backer G. Catapano A.L. Hegele R.A. Kees Hovingh G. Jacobson T.A. Leiter L. Mach F. Wiklund O. Statin-associated muscle symptoms: Impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, etiology, and management. Eur. Heart J. 2015 36 17 1012 1022 10.1093/eurheartj/ehv043 25694464
    [Google Scholar]
  16. Shapiro M.D. Tavori H. Fazio S. PCSK9. Circ. Res. 2018 122 10 1420 1438 10.1161/CIRCRESAHA.118.311227 29748367
    [Google Scholar]
  17. Moriarty P.M. Gibson C.A. Slaughter M.S. Efficacy and safety of alirocumab and evolocumab in patients with statin intolerance or muscle-related side effects: A systematic review and meta-analysis. Cardiol. Clin. 2018 36 2 201 210 10.1016/j.ccl.2017.12.009
    [Google Scholar]
  18. Nicholls S.J. Puri R. Anderson T. Ballantyne C.M. Cho L. Kastelein J.J.P. Koenig W. Somaratne R. Kassahun H. Yang J. Wasserman S.M. Scott R. Ungi I. Podolec J. Ophuis A.O. Cornel J.H. Borgman M. Brennan D.M. Nissen S.E. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA 2016 316 22 2373 2384 10.1001/jama.2016.16951 27846344
    [Google Scholar]
  19. Koskinas K.C. Windecker S. Räber L. Proprotein convertase subtilisin/kexin type 9 inhibition: Insights from clinical trials and future perspectives. Circulation 2018 137 22 2218 2230 10.1161/CIRCULATIONAHA.117.030330
    [Google Scholar]
  20. Schwartz G.G. Bessac L. Berdan L.G. Effect of alirocumab added to high-intensity statin therapy on cardiovascular outcomes in patients with acute coronary syndrome: ODYSSEY OUTCOMES trial. Circulation 2018 138 23 2401 2411 10.1161/CIRCULATIONAHA.118.038840
    [Google Scholar]
  21. Koren M.J. Sabatine M.S. Giugliano R.P. Long-term efficacy and safety of deficient levels of low-density lipoprotein cholesterol: A review of the PCSK9 inhibitor evolocumab. J. Am. Heart Assoc. 2017 6 12 e007019 10.1161/JAHA.117.007019
    [Google Scholar]
  22. Hajar R PCSK 9 inhibitors: A short history and a new era of lipid-lowering therapy. Heart Views 2019 20 2 74 75 10.4103/HEARTVIEWS.HEARTVIEWS_59_19
    [Google Scholar]
  23. Elguindy A. Yacoub M.H. The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research. Glob. Cardiol. Sci. Pract. 2013 2013 4 39 10.5339/gcsp.2013.39 24749106
    [Google Scholar]
  24. Leren T.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin. Genet. 2004 65 5 419 422 10.1111/j.0009‑9163.2004.0238.x 15099351
    [Google Scholar]
  25. Ference B.A. Ginsberg H.N. Graham I. Ray K.K. Packard C.J. Bruckert E. Hegele R.A. Krauss R.M. Raal F.J. Schunkert H. Watts G.F. Borén J. Fazio S. Horton J.D. Masana L. Nicholls S.J. Nordestgaard B.G. van de Sluis B. Taskinen M.R. Tokgözoğlu L. Landmesser U. Laufs U. Wiklund O. Stock J.K. Chapman M.J. Catapano A.L. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017 38 32 2459 2472 10.1093/eurheartj/ehx144 28444290
    [Google Scholar]
  26. Arsenault B.J. Petrides F. Tardif J.C. Emerging treatment options for hypercholesterolemia. Nat. Rev. Cardiol. 2021 18 2 99 111 10.1038/s41569‑020‑00464‑y
    [Google Scholar]
  27. Ridker P.M. Everett B.M. Pradhan A. Low-density lipoprotein cholesterol reduction with bococizumab and cardiovascular outcomes. N. Engl. J. Med. 2017 376 16 1427 1437 10.1056/NEJMoa1701488 28304242
    [Google Scholar]
  28. Ballantyne C.M. Banach M. Mancini G.B. Efficacy and safety of bempedoic acid in patients with statin intolerance. J. Am. Heart Assoc. 2020 9 7 e016262 10.1161/JAHA.119.016262
    [Google Scholar]
  29. Sabatine M.S. Leiter L.A. Wiviott S.D. Cardiovascular safety and efficacy of inclisiran in patients with elevated LDL cholesterol levels. Eur. Heart J. 2020 41 21 1939 1949 10.1093/eurheartj/ehaa407
    [Google Scholar]
  30. Cohen J. Pertsemlidis A. Kotowski I.K. Graham R. Garcia C.K. Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 2005 37 2 161 165 10.1038/ng1509 15654334
    [Google Scholar]
  31. Navarese E.P. Robinson J.G. Kowalewski M. Kolodziejczak M. Andreotti F. Bliden K. Tantry U. Kubica J. Raggi P. Gurbel P.A. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. JAMA 2018 319 15 1566 1579 10.1001/jama.2018.2525 29677301
    [Google Scholar]
  32. Khan S.U. Riaz H. Rahman H. Khan M.U. Khan M.S. Alkhouli M. Kaluski E. Leucker T.M. Blaha M.J. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. J. Clin. Lipidol. 2019 13 4 538 549 10.1016/j.jacl.2019.05.014 31278046
    [Google Scholar]
  33. Rosenson R.S. Hegele R.A. Fazio S. The future of PCSK9 inhibitors. Curr. Atheroscler. Rep. 2021 23 7 29 10.1007/s11883‑021‑00918‑z
    [Google Scholar]
  34. Cannon C.P. Blazing M.A. Giugliano R.P. McCagg A. White J.A. Theroux P. Darius H. Lewis B.S. Ophuis T.O. Jukema J.W. De Ferrari G.M. Ruzyllo W. De Lucca P. Im K. Bohula E.A. Reist C. Wiviott S.D. Tershakovec A.M. Musliner T.A. Braunwald E. Califf R.M. Ezetimibe is added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015 372 25 2387 2397 10.1056/NEJMoa1410489 26039521
    [Google Scholar]
  35. Wong N.D. Young D. Zhao Y. Statin use and attainment of low-density lipoprotein cholesterol goals in high-risk patients with dyslipidemia. J. Clin. Lipidol. 2017 11 3 649 662 10.1016/j.jacl.2017.02.009
    [Google Scholar]
  36. Landmesser U. Chapman M.J. Stock J.K. PCSK9 inhibition in patients with dyslipidemia. Circ. Res. 2019 124 1 752 770 10.1161/CIRCRESAHA.116.316293
    [Google Scholar]
  37. Gencer B. Koskinas K.C. Räber L. PCSK9 inhibitors in clinical practice: What the cardiologist needs to know. Eur. Heart J. 2021 42 1 100 112 10.1093/eurheartj/ehaa825
    [Google Scholar]
  38. Moriarty P.M. McKenney J.M. Koschinsky M.L. Lipoprotein(a) and cardiovascular disease: Current and future therapies. J. Clin. Lipidol. 2022 16 2 150 165 10.1016/j.jacl.2022.01.009
    [Google Scholar]
  39. Nicholls S.J. Puri R. Wolski K. Impact of PCSK9 inhibition with evolocumab on coronary plaque composition. Eur. Heart J. 2018 39 13 1269 1278 10.1093/eurheartj/ehx799 29618033
    [Google Scholar]
  40. Hao Q. Aertgeerts B. Guyatt G. Bekkering G.E. Vandvik P.O. Khan S.U. Rodondi N. Jackson R. Reny J.L. Al Ansary L. Van Driel M. Assendelft W.J.J. Agoritsas T. Spencer F. Siemieniuk R.A.C. Lytvyn L. Heen A.F. Zhao Q. Riaz I.B. Ramaekers D. Okwen P.M. Zhu Y. Dawson A. Ovidiu M.C. Vanbrabant W. Li S. Delvaux N. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: A clinical practice guideline with risk-stratified recommendations. BMJ 2022 377 e069066 10.1136/bmj‑2021‑069066 35508320
    [Google Scholar]
  41. Higgins J.P.T. Altman D.G. Gøtzsche P.C. Jüni P. Moher D. Oxman A.D. Savovic J. Schulz K.F. Weeks L. Sterne J.A.C. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011 343 oct18 2 d5928 10.1136/bmj.d5928 22008217
    [Google Scholar]
  42. Manager R. Welcome to RevMan 5.4 2020 Available from: https://training.cochrane.org/system/files/uploads/protected_file/RevMan5.4_user_guide.pdf
  43. Haddaway N.R. Page M.J. Pritchard C.C. McGuinness L.A. PRISMA2020 : An R package and Shiny app for producing PRISMA 2020‐compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst. Rev. 2022 18 2 e1230 10.1002/cl2.1230 36911350
    [Google Scholar]
  44. Nicholls S.J. Kataoka Y. Nissen S.E. Prati F. Windecker S. Puri R. Hucko T. Aradi D. Herrman J.P.R. Hermanides R.S. Wang B. Wang H. Butters J. Di Giovanni G. Jones S. Pompili G. Psaltis P.J. Effect of evolocumab on coronary plaque phenotype and burden in Statin-Treated Patients following myocardial infarction. JACC Cardiovasc. Imaging 2022 15 7 1308 1321 10.1016/j.jcmg.2022.03.002 35431172
    [Google Scholar]
  45. Hao Y. Yang Y. Wang Y. Li J. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int. Heart J. 2022 63 4 669 677 10.1536/ihj.22‑052 35831153
    [Google Scholar]
  46. Mehta S.R. Pare G. Lonn E.M. Jolly S.S. Natarajan M.K. Pinilla-Echeverri N. Schwalm J.D. Sheth T.N. Sibbald M. Tsang M. Valettas N. Velianou J.L. Lee S.F. Ferdous T. Nauman S. Nguyen H. McCready T. McQueen M.J. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A randomised, double-blind, sham-controlled trial. EuroIntervention 2022 18 11 e888 e896 10.4244/EIJ‑D‑22‑00735 36349701
    [Google Scholar]
  47. Raal F. Durst R. Bi R. Talloczy Z. Maheux P. Lesogor A. Kastelein J.J.P. Efficacy, safety, and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia: Results from the ORION-5 randomized clinical trial. Circulation 2024 149 5 354 362 10.1161/CIRCULATIONAHA.122.063460 37850379
    [Google Scholar]
  48. Schwartz G.G. Szarek M. Bittner V.A. Diaz R. Goodman S.G. Jukema J.W. Landmesser U. López-Jaramillo P. Manvelian G. Pordy R. Scemama M. Sinnaeve P.R. White H.D. Gabriel Steg P. Lipoprotein(A) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol. J. Am. Coll. Cardiol. 2021 78 5 421 433 10.1016/j.jacc.2021.04.102 34325831
    [Google Scholar]
  49. Albosta M.S. Grant J.K. Taub P. Blumenthal R.S. Martin S.S. Michos E.D. Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc. Health Risk Manag. 2023 19 421 431 10.2147/VHRM.S338424 37434791
    [Google Scholar]
  50. Gao F. Wang Z.J. Ma X.T. Shen H. Yang L.X. Zhou Y.J. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography. Lipids Health Dis. 2021 20 1 106 10.1186/s12944‑021‑01528‑3 34511134
    [Google Scholar]
  51. Rexhaj E. Bär S. Soria R. Ueki Y. Häner J.D. Otsuka T. Kavaliauskaite R. Siontis G.C.M. Stortecky S. Shibutani H. Spirk D. Engstrøm T. Lang I. Morf L. Ambühl M. Windecker S. Losdat S. Koskinas K.C. Räber L. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy. Atherosclerosis 2024 392 117504 10.1016/j.atherosclerosis.2024.117504 38513436
    [Google Scholar]
  52. Janik M.J. Urbach D.V. van Nieuwenhuizen E. Zhao J. Yellin O. Baccara-Dinet M.T. Pordy R. Manvelian G. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomized, placebo-controlled study. Atherosclerosis 2021 331 20 27 10.1016/j.atherosclerosis.2021.06.913 34303265
    [Google Scholar]
  53. Schwartz G.G. Steg P.G. Szarek M. Bhatt D.L. Bittner V.A. Diaz R. Edelberg J.M. Goodman S.G. Hanotin C. Harrington R.A. Jukema J.W. Lecorps G. Mahaffey K.W. Moryusef A. Pordy R. Quintero K. Roe M.T. Sasiela W.J. Tamby J.F. Tricoci P. White H.D. Zeiher A.M. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 2018 379 22 2097 2107 10.1056/NEJMoa1801174 30403574
    [Google Scholar]
  54. Banach M. Rizzo M. Nikolic D. Statin intolerance – An attempt to resolve one of the most important issues in cardiology. Int. J. Cardiol. 2015 211 128 135 10.1016/j.ijcard.2015.05.124
    [Google Scholar]
  55. Puri R. Nissen S.E. Shao M. Impact of statins on coronary atheroma progression. JAMA 2014 311 3 233 243 10.1001/jama.2013.282542 24430308
    [Google Scholar]
  56. Ference B.A. Ginsberg H.N. Graham I. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 2. Mechanistic insights from genetic studies. Eur. Heart J. 2017 38 32 2469 2477 10.1093/eurheartj/ehx144 28444290
    [Google Scholar]
  57. Ballantyne C.M. Banach M. Mancini G.B. Safety and efficacy of PCSK9 inhibitors. Nat. Rev. Cardiol. 2021 18 2 88 90 10.1038/s41569‑021‑00462‑0
    [Google Scholar]
  58. Toth P.P. Banach M. Farnier M. PCSK9 inhibition in high-risk cardiovascular patients. Cardiol. Clin. 2020 38 1 115 128 10.1016/j.ccl.2019.08.007 31753170
    [Google Scholar]
  59. Wang X. Wen D. Chen Y. Ma L. You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: A bayesian network meta-analysis. Cardiovasc. Diabetol. 2022 21 1 107 10.1186/s12933‑022‑01542‑4 35706032
    [Google Scholar]
  60. Ali R. Banach M. Wong N.D. Global burden of dyslipidemia. Circulation 2019 139 6 566 578 10.1161/CIRCULATIONAHA.118.038639
    [Google Scholar]
  61. Grundy S.M. Cleeman J.I. Merz C.N.B. Brewer H.B. Jr Clark L.T. Hunninghake D.B. Pasternak R.C. Smith S.C. Jr Stone N.J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004 110 2 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516
    [Google Scholar]
  62. Cannon C.P. Blazing M.A. Giugliano R.P. Adding ezetimibe to statin therapy improves cardiovascular outcomes. Circulation 2015 131 22 1969 1970 10.1161/CIR.0000000000000186
    [Google Scholar]
  63. Laufs U. Descamps O.S. Catapano A.L. Practical recommendations for the use of PCSK9 inhibitors in clinical practice: Translating guidelines into practice. Cardiovasc. Drugs Ther. 2020 34 1 1 10 10.1007/s10557‑019‑06925‑z 32034644
    [Google Scholar]
  64. Landmesser U. Chapman M.J. Farnier M. LDL-cholesterol lowering beyond statins: The PCSK9 inhibitor era. Eur. Heart J. 2017 38 36 2943 2949 10.1093/eurheartj/ehx382
    [Google Scholar]
  65. Giugliano R.P. Pedersen T.R. Park J.G. Baseline lipoprotein(a) and clinical outcomes with PCSK9 inhibition in Fourier. Circulation 2018 138 14 1550 1559 10.1161/CIRCULATIONAHA.118.035909
    [Google Scholar]
  66. Banach M. Serban M.C. Sahebkar A. Impact of statin therapy on plasma coenzyme Q10 concentrations: A systematic review and meta-analysis. Mayo Clin. Proc. 2015 90 1 24 34 10.1016/j.mayocp.2014.08.021 25440725
    [Google Scholar]
  67. Koskinas K.C. Siontis G.C.M. Piccolo R. Efficacy and safety of low-density lipoprotein cholesterol lowering by PCSK9 inhibition: An analysis of patient-level data. Lancet 2018 391 10126 641 651 10.1016/S0140‑6736(17)32337‑5
    [Google Scholar]
  68. Cannon C.P. Steg P.G. Szarek M. Alirocumab in patients after acute coronary syndrome. N. Engl. J. Med. 2015 372 25 2387 2397 10.1056/NEJMoa1410489 26039521
    [Google Scholar]
  69. Baigent C. Keech A. Kearney P.M. Blackwell L. Buck G. Pollicino C. Kirby A. Sourjina T. Peto R. Collins R. Simes R. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 9493 1267 1278 10.1016/S0140‑6736(05)67394‑1 16214597
    [Google Scholar]
  70. Mihaylova B. Emberson J. Blackwell L. Keech A. Simes J. Barnes E.H. Voysey M. Gray A. Collins R. Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012 380 9841 581 590 10.1016/S0140‑6736(12)60367‑5 22607822
    [Google Scholar]
  71. Collins R. Armitage J. Parish S. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002 360 9326 7 22 10.1016/S0140‑6736(02)09327‑3 12114036
    [Google Scholar]
  72. Fulcher J. O’Connell R. Voysey M. Emberson J. Blackwell L. Mihaylova B. Simes J. Collins R. Kirby A. Colhoun H. Braunwald E. La Rosa J. Pedersen T.R. Tonkin A. Davis B. Sleight P. Franzosi M.G. Baigent C. Keech A. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015 385 9976 1397 1405 10.1016/S0140‑6736(14)61368‑4 25579834
    [Google Scholar]
  73. Dugré N. Lindblad A.J. Perry D. Allan G.M. Braschi É. Falk J. Froentjes L. Garrison S.R. Kirkwood J.E.M. Korownyk C.S. McCormack J.P. Moe S.S. Paige A. Potter J. Thomas B.S. Ton J. Young J. Weresch J. Kolber M.R. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Can. Fam. Physician 2023 69 10 701 711 10.46747/cfp.6910701 37833094
    [Google Scholar]
  74. Oikonomou E.K. Psaltopoulou T. Georgiopoulos G. Lipid-lowering agents beyond statins: Meta-analysis and meta-regression of randomized controlled trials. J. Am. Coll. Cardiol. 2020 75 12 1496 1507 10.1016/j.jacc.2020.01.045
    [Google Scholar]
  75. Sabatine M.S. Giugliano R.P. Keech A.C. Honarpour N. Wiviott S.D. Murphy S.A. Kuder J.F. Wang H. Liu T. Wasserman S.M. Sever P.S. Pedersen T.R. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 2017 376 18 1713 1722 10.1056/NEJMoa1615664 28304224
    [Google Scholar]
  76. Cannon C.P. Blazing M.A. Giugliano R.P. McCagg A. White J.A. Theroux P. Darius H. Lewis B.S. Ophuis T.O. Jukema J.W. De Ferrari G.M. Ruzyllo W. De Lucca P. Im K. Bohula E.A. Reist C. Wiviott S.D. Tershakovec A.M. Musliner T.A. Braunwald E. Califf R.M. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015 372 25 2387 2397 10.1056/NEJMoa1410489 26039521
    [Google Scholar]
  77. Bhatt D.L. Steg P.G. Miller M. Brinton E.A. Jacobson T.A. Ketchum S.B. Doyle R.T. Jr Juliano R.A. Jiao L. Granowitz C. Tardif J.C. Ballantyne C.M. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 2019 380 1 11 22 10.1056/NEJMoa1812792 30415628
    [Google Scholar]
  78. Moriarty P.M. Cannon C.P. Toth P.P. Inclisiran for LDL cholesterol reduction: A pooled analysis of phase 3 trials. J. Am. Coll. Cardiol. 2021 77 9 1182 1190 10.1016/j.jacc.2021.01.016 33663735
    [Google Scholar]
  79. Colhoun H.M. Ginsberg H.N. Robinson J.G. Inclisiran and cardiovascular event reduction in patients with elevated lipoprotein(a): Analysis of the ORION-4 trial. Lancet 2021 398 10303 1403 1410 10.1016/S0140‑6736(21)01235‑1
    [Google Scholar]
  80. Toth P.P. Philip S. Hull M. Granowitz C. Elevated lipoprotein(a) and the efficacy of PCSK9 inhibition with alirocumab: Insights from ODYSSEY OUTCOMES. Circulation 2020 141 20 1605 1614 10.1161/CIRCULATIONAHA.119.045183
    [Google Scholar]
  81. Koskinas K.C. Räber L. Windecker S. PCSK9 inhibitors for secondary prevention in patients with cardiovascular disease: A Bayesian meta-analysis. Cardiovasc. Diabetol. 2020 19 1 111 10.1186/s12933‑020‑01090‑1 32646432
    [Google Scholar]
/content/journals/ccr/10.2174/011573403X345749250122092324
Loading
The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/011573403X345749250122092324
/content/journals/ccr/10.2174/011573403X345749250122092324
/content/journals/ccr/10.2174/011573403X345749250122092324
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: ezetimibe ; atherosclerotic cardiovascular disease (ASCVD) ; LDL cholesterol reduction ; PCSK9 inhibitors ; major adverse cardiovascular events (MACE) ; lipid-lowering agents ; cardiovascular risk reduction ; statin therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test